$10.60
1.15% today
Nasdaq, Feb 05, 04:18 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$10.48
+2.55 32.16% 1M
+6.42 158.13% 6M
+2.38 29.38% YTD
+7.50 251.68% 1Y
+6.44 159.41% 3Y
+3.84 57.83% 5Y
-5.37 33.88% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.62 6.29%
ISIN
US21900C3088
Symbol
CRMD
Sector

Key metrics

Market capitalization $635.90m
Enterprise Value $590.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 48.16
P/S ratio (TTM) P/S ratio 51.87
P/B ratio (TTM) P/B ratio 10.33
Revenue growth (TTM) Revenue growth 41,184.20%
Revenue (TTM) Revenue $12.26m
EBIT (operating result TTM) EBIT $-50.96m
Free Cash Flow (TTM) Free Cash Flow $-56.15m
Cash position $46.03m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 16.08
EV/Sales forward 14.93
Short interest 11.69%
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CorMedix Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a CorMedix Inc forecast:

Buy
100%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
12 12
40,767% 40,767%
100%
- Direct Costs 2.07 2.07
886% 886%
17%
10 10
5,761% 5,761%
83%
- Selling and Administrative Expenses 56 56
104% 104%
459%
- Research and Development Expense 4.50 4.50
67% 67%
37%
-51 -51
22% 22%
-413%
- Depreciation and Amortization 0.34 0.34
62% 62%
3%
EBIT (Operating Income) EBIT -51 -51
22% 22%
-416%
Net Profit -46 -46
16% 16%
-376%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Neutral
GlobeNewsWire
29 days ago
‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today annou...
Neutral
GlobeNewsWire
about 2 months ago
BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). CorMedix's addition to the NBI will become effective prior to the market open ...
Neutral
GlobeNewsWire
2 months ago
BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services (CMS) and the Center for Medicare a...
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 82
Founded 2006
Website www.cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today